{
  "Trajectory0": [
    {
      "question_id": 0,
      "question_type": "RAG",
      "question": "According to the knowledge base, what were the primary histological types of NSCLC included in the study?",
      "ground_truth": "The primary histological types of NSCLC included in the study were adenocarcinoma and squamous cell carcinoma."
    },
    {
      "question_id": 1,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the average age of patients diagnosed with adenocarcinoma?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT AVG(Age_at_Histological_Diagnosis) FROM clinical_genomic WHERE Histology = 'Adenocarcinoma';",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Age_at_Histological_Diagnosis: INT - Histology: VARCHAR(70)",
        "ground_truth_query_result": "67",
        "ground_truth_answer": "Based on the SQL query results, the average age of patients diagnosed with adenocarcinoma is 67 years old."
      }
    },
    {
      "question_id": 2,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the most common pathological T stage for squamous cell carcinoma?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Pathological_T_stage, COUNT(*) as Count FROM clinical_genomic WHERE Histology = 'Squamous cell carcinoma' GROUP BY Pathological_T_stage ORDER BY Count DESC LIMIT 1;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Histology: VARCHAR(70) - Pathological_T_stage: VARCHAR(20)",
        "ground_truth_query_result": "T2a",
        "ground_truth_answer": "For patients with squamous cell carcinoma, the most common pathological T stage is T2a, according to the query results."
      }
    }
  ],
  "Trajectory1": [
    {
      "question_id": 3,
      "question_type": "RAG",
      "question": "According to the knowledge base, how did the EGF pathway associate with CT imaging features?",
      "ground_truth": "The EGF pathway was significantly correlated with the presence of ground-glass opacity and irregular nodules or nodules with poorly defined margins."
    },
    {
      "question_id": 4,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What percentage of patients have EGFR mutations?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT (COUNT(CASE WHEN EGFR_mutation_status = 'Mutant' THEN 1 END) * 100.0 / COUNT(*)) AS percentage FROM clinical_genomic;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - EGFR_mutation_status: VARCHAR(50)",
        "ground_truth_query_result": "14.285714",
        "ground_truth_answer": "According to the query results, approximately 14.29% of patients in the clinical_genomic table have EGFR mutations."
      }
    }
  ],
  "Trajectory2": [
    {
      "question_id": 5,
      "question_type": "RAG",
      "question": "According to the knowledge base, what was the main purpose of this radiogenomic study?",
      "ground_truth": "The main purpose was to create a radiogenomic map linking CT image features and gene expression profiles generated by RNA sequencing for patients with non-small cell lung cancer (NSCLC)."
    },
    {
      "question_id": 6,
      "question_type": "RAG",
      "question": "According to the knowledge base, how many patients with NSCLC were included in the study cohort?",
      "ground_truth": "The study included 113 patients with NSCLC."
    },
    {
      "question_id": 7,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the distribution of patients across different ethnicities?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Ethnicity, COUNT(*) as Count FROM clinical_genomic GROUP BY Ethnicity;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Ethnicity: VARCHAR(50)",
        "ground_truth_query_result": "Caucasian: 92, Hispanic/Latino: 5, Native Hawaiian/Pacific Islander: 1, African-American: 3, Asian: 18",
        "ground_truth_answer": "The distribution of patients across different ethnicities is as follows: Caucasian: 92, Hispanic/Latino: 5, Native Hawaiian/Pacific Islander: 1, African-American: 3, Asian: 18. This shows that the majority of patients in the study are Caucasian."
      }
    },
    {
      "question_id": 8,
      "question_type": "CUSTOM",
      "question": "Can you compute the imaging biomarkers for these 2 patients with patient IDs of R01-083 and R01-040?",
      "ground_truth": ""
    },
    {
      "question_id": 9,
      "question_type": "CUSTOM",
      "question": "Can you compute the imaging biomarkers for the 2 patients with the lowest CD4 expression values?",
      "ground_truth": ""
    }
  ],
  "Trajectory3": [
    {
      "question_id": 10,
      "question_type": "RAG",
      "question": "According to the knowledge base, what are the two main types of lung cancer examined in this study?",
      "ground_truth": "The study examined adenocarcinoma and squamous cell carcinoma, which are types of non-small cell lung cancer (NSCLC)."
    },
    {
      "question_id": 11,
      "question_type": "TEXT2SQL",
      "question": "According to the database, how many patients have each type of lung cancer histology?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Histology, COUNT(*) as patient_count FROM clinical_genomic GROUP BY Histology",
        "ground_truth_sql_context": "[{'table_name': 'clinical_genomic', 'columns': [('Case_ID', 'VARCHAR(50)'), ('LRIG1', 'FLOAT'), ('HPGD', 'FLOAT'), ('GDF15', 'FLOAT'), ('CDH2', 'FLOAT'), ('POSTN', 'FLOAT'), ('VCAN', 'FLOAT'), ('PDGFRA', 'FLOAT'), ('VCAM1', 'FLOAT'), ('CD44', 'FLOAT'), ('CD48', 'FLOAT'), ('CD4', 'FLOAT'), ('LYL1', 'FLOAT'), ('SPI1', 'FLOAT'), ('CD37', 'FLOAT'), ('VIM', 'FLOAT'), ('LMO2', 'FLOAT'), ('EGR2', 'FLOAT'), ('BGN', 'FLOAT'), ('COL4A1', 'FLOAT'), ('COL5A1', 'FLOAT'), ('COL5A2', 'FLOAT'), ('Patient_affiliation', 'VARCHAR(50)'), ('Age_at_Histological_Diagnosis', 'INT'), ('Weight_lbs', 'FLOAT'), ('Gender', 'VARCHAR(10)'), ('Ethnicity', 'VARCHAR(50)'), ('Smoking_status', 'VARCHAR(50)'), ('Pack_Years', 'INT'), ('Histology', 'VARCHAR(70)'), ('Pathological_T_stage', 'VARCHAR(20)'), ('Pathological_N_stage', 'VARCHAR(20)'), ('Pathological_M_stage', 'VARCHAR(20)'), ('Histopathological_Grade', 'VARCHAR(70)'), ('Lymphovascular_invasion', 'VARCHAR(60)'), ('Pleural_invasion', 'VARCHAR(50)'), ('EGFR_mutation_status', 'VARCHAR(50)'), ('KRAS_mutation_status', 'VARCHAR(50)'), ('ALK_translocation_status', 'VARCHAR(50)'), ('Adjuvant_Treatment', 'VARCHAR(20)'), ('Chemotherapy', 'VARCHAR(20)'), ('Radiation', 'VARCHAR(20)'), ('Recurrence', 'VARCHAR(20)'), ('Recurrence_Location', 'VARCHAR(50)'), ('Survival_Status', 'BOOLEAN'), ('Survival_Duration', 'FLOAT')]}, {'table_name': 'chemotherapy_survival', 'columns': [('LRIG1', 'FLOAT'), ('Survival_Status', 'BOOLEAN'), ('Survival_Duration', 'FLOAT'), ('ExpressionGroup', 'FLOAT')]}]",
        "ground_truth_query_result": "[{'Histology': 'Adenocarcinoma', 'patient_count': 88}, {'Histology': 'Squamous cell carcinoma', 'patient_count': 28}, {'Histology': 'NSCLC NOS (not otherwise specified)', 'patient_count': 3}]",
        "ground_truth_answer": "There are 88 patients with adenocarcinoma, 28 with squamous cell carcinoma, and 3 with other types of NSCLC."
      }
    },
    {
      "question_id": 12,
      "question_type": "CUSTOM",
      "question": "Can you compute the imaging biomarkers for the 2 patients with the lowest gdf15 expression values and then highlight the elongation and sphericity of the tumor with these patients?",
      "ground_truth": ""
    }
  ],
  "Trajectory4": [
    {
      "question_id": 13,
      "question_type": "RAG",
      "question": "Based on the knowledge base, what categories of smoking status were recorded for lung cancer patients in this study?",
      "ground_truth": "The study collected smoking status data for patients, categorizing them as current smokers, former smokers, or never smokers. They also tracked pack years for smokers."
    },
    {
      "question_id": 14,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the average number of pack years for each smoking status category?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Smoking_status, AVG(Pack_Years) as avg_pack_years FROM clinical_genomic GROUP BY Smoking_status",
        "ground_truth_sql_context": "[{'table_name': 'clinical_genomic', 'columns': [('Case_ID', 'VARCHAR(50)'), ('LRIG1', 'FLOAT'), ('HPGD', 'FLOAT'), ('GDF15', 'FLOAT'), ('CDH2', 'FLOAT'), ('POSTN', 'FLOAT'), ('VCAN', 'FLOAT'), ('PDGFRA', 'FLOAT'), ('VCAM1', 'FLOAT'), ('CD44', 'FLOAT'), ('CD48', 'FLOAT'), ('CD4', 'FLOAT'), ('LYL1', 'FLOAT'), ('SPI1', 'FLOAT'), ('CD37', 'FLOAT'), ('VIM', 'FLOAT'), ('LMO2', 'FLOAT'), ('EGR2', 'FLOAT'), ('BGN', 'FLOAT'), ('COL4A1', 'FLOAT'), ('COL5A1', 'FLOAT'), ('COL5A2', 'FLOAT'), ('Patient_affiliation', 'VARCHAR(50)'), ('Age_at_Histological_Diagnosis', 'INT'), ('Weight_lbs', 'FLOAT'), ('Gender', 'VARCHAR(10)'), ('Ethnicity', 'VARCHAR(50)'), ('Smoking_status', 'VARCHAR(50)'), ('Pack_Years', 'INT'), ('Histology', 'VARCHAR(70)'), ('Survival_Status', 'BOOLEAN'), ('Survival_Duration', 'FLOAT')]}, {'table_name': 'chemotherapy_survival', 'columns': [('LRIG1', 'FLOAT'), ('Survival_Status', 'BOOLEAN'), ('Survival_Duration', 'FLOAT'), ('ExpressionGroup', 'FLOAT')]}]",
        "ground_truth_query_result": "[{'Smoking_status': 'Current', 'avg_pack_years': 45}, {'Smoking_status': 'Former', 'avg_pack_years': 41}, {'Smoking_status': 'Never', 'avg_pack_years': 0}]",
        "ground_truth_answer": "Current smokers have an average of 45 pack years, former smokers have an average of 41 pack years, and never smokers have 0 pack years."
      }
    }
  ],
  "Trajectory5": [
    {
      "question_id": 15,
      "question_type": "RAG",
      "question": "According to the knowledge base, what imaging modality was used in this radiogenomic study?",
      "ground_truth": "Computed tomography (CT) was the imaging modality used in this radiogenomic study."
    },
    {
      "question_id": 16,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the average number of days between CT and surgery for all patients?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT AVG(Days_between_CT_and_surgery) FROM clinical_genomic;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Days_between_CT_and_surgery: INT",
        "ground_truth_query_result": "52",
        "ground_truth_answer": "The average number of days between CT and surgery is 52 days."
      }
    }
  ],
  "Trajectory6": [
    {
      "question_id": 17,
      "question_type": "RAG",
      "question": "According to the knowledge base, how many patients were included in the study?",
      "ground_truth": "The study included 113 patients with NSCLC."
    },
    {
      "question_id": 18,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the gender distribution among patients?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Gender, COUNT(*) as Count FROM clinical_genomic GROUP BY Gender;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Gender: VARCHAR(10)",
        "ground_truth_query_result": "Male: 87, Female: 32",
        "ground_truth_answer": "The gender distribution among patients is as follows: Male: 87, Female: 32. This indicates that there are significantly more male patients than female patients in this study."
      }
    }
  ],
  "Trajectory7": [
    {
      "question_id": 19,
      "question_type": "RAG",
      "question": "According to the knowledge base, what treatments were tracked for patients in this study?",
      "ground_truth": "The study tracked whether patients received adjuvant treatment, chemotherapy, and radiation therapy."
    },
    {
      "question_id": 20,
      "question_type": "TEXT2SQL",
      "question": "According to the database, How many patients received both chemotherapy and radiation?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT COUNT(*) FROM clinical_genomic WHERE Chemotherapy = 'Yes' AND Radiation = 'Yes';",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Chemotherapy: VARCHAR(20) - Radiation: VARCHAR(20)",
        "ground_truth_query_result": "12",
        "ground_truth_answer": "The query results indicate that 12 patients received both chemotherapy and radiation treatment."
      }
    },
    {
      "question_id": 21,
      "question_type": "CUSTOM",
      "question": "What is the best gene biomarker (lowest p value) with overall survival for patients that have undergone chemotherapy?",
      "ground_truth": ""
    },
    {
      "question_id": 22,
      "question_type": "CUSTOM",
      "question": "Generate a bar chart of the top 5 gene biomarkers based on their p value and include their names in the x axis.",
      "ground_truth": ""
    }
  ],
  "Trajectory8": [
    {
      "question_id": 23,
      "question_type": "RAG",
      "question": "According to the knowledge base, what was the date range for NSCLC diagnosis in the study cohort?",
      "ground_truth": "The patients were diagnosed between April 2008 and September 2014."
    },
    {
      "question_id": 24,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the average age of all patients at diagnosis?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT AVG(Age_at_Histological_Diagnosis) FROM clinical_genomic;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Age_at_Histological_Diagnosis: INT",
        "ground_truth_query_result": "68",
        "ground_truth_answer": "The average age at histological diagnosis is 68 years."
      }
    }
  ],
  "Trajectory9": [
    {
      "question_id": 25,
      "question_type": "RAG",
      "question": "According to the knowledge base, how many semantic image features were initially recorded for each tumor?",
      "ground_truth": "Initially, 87 semantic image features were recorded for each tumor."
    },
    {
      "question_id": 26,
      "question_type": "TEXT2SQL",
      "question": "According to the database, How many patients have lymphovascular invasion?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT COUNT(*) FROM clinical_genomic WHERE Lymphovascular_invasion = 'Present';",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Lymphovascular_invasion: VARCHAR(60)",
        "ground_truth_query_result": "16",
        "ground_truth_answer": "The query results indicate that 16 patients have lymphovascular invasion."
      }
    }
  ],
  "Trajectory10": [
    {
      "question_id": 27,
      "question_type": "RAG",
      "question": "According to the knowledge base, what tool was used to assess the survival relationship of the metagenes?",
      "ground_truth": "PRECOG was used to assess the survival relationship of the metagenes."
    },
    {
      "question_id": 28,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the survival status distribution among patients?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Survival_Status, COUNT(*) as Count FROM clinical_genomic GROUP BY Survival_Status;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Survival_Status: BOOLEAN",
        "ground_truth_query_result": "true:42 , false: 77",
        "ground_truth_answer": "The survival status distribution is as follows: 42 patients are alive and 77 patients are deceased."
      }
    }
  ],
  "Trajectory11": [
    {
      "question_id": 29,
      "question_type": "RAG",
      "question": "According to the knowledge base, what was the name of the open-source platform used to facilitate selection of semantic image features?",
      "ground_truth": "The open-source ePAD platform was used to facilitate selection of semantic image features."
    },
    {
      "question_id": 30,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the distribution of nodule attenuation types?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Percent_GG, COUNT(*) as Count FROM clinical_genomic GROUP BY Percent_GG ORDER BY Percent_GG;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Nodule_attenuation: VARCHAR(50)",
        "ground_truth_query_result": "[{'Percent_GG': '0%', 'Count': 66}, {'Percent_GG': '1-25%', 'Count': 24}, {'Percent_GG': '25-50%', 'Count': 4}, {'Percent_GG': '50-75%', 'Count': 6}, {'Percent_GG': '75-<100%', 'Count': 5}, {'Percent_GG': '100%', 'Count': 1}, {'Percent_GG': 'Not Assessed', 'Count': 13}]",
        "ground_truth_answer": "The distribution of nodule attenuation types is: Solid: 89, Part-solid: 18, Ground glass: 6."
      }
    }
  ],
  "Trajectory12": [
    {
      "question_id": 31,
      "question_type": "RAG",
      "question": "According to the knowledge base, how many highly coexpressed gene clusters (metagenes) were identified?",
      "ground_truth": "Ten highly coexpressed gene clusters, termed metagenes, were identified."
    },
    {
      "question_id": 32,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the average expression value of the LRIG1 gene?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT AVG(LRIG1) FROM clinical_genomic;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - LRIG1: FLOAT",
        "ground_truth_query_result": "22.3557",
        "ground_truth_answer": "The average expression value of the LRIG1 gene is 22.36."
      }
    },
    {
      "question_id": 33,
      "question_type": "CUSTOM",
      "question": "Show me a Kaplan-Meier chart for biomarker with name 'LRIG1' for chemotherapy patients by grouping expression values less than 10 and greater than or equal to 10",
      "ground_truth": ""
    }
  ],
  "Trajectory13": [
    {
      "question_id": 34,
      "question_type": "RAG",
      "question": "According to the knowledge base, what statistical methods were used to build the radiogenomics map?",
      "ground_truth": "The t statistic and the Spearman correlation metric with multiple testing correction were used to build the radiogenomics map."
    },
    {
      "question_id": 35,
      "question_type": "TEXT2SQL",
      "question": "According to the database, What is the distribution of pathological N stages?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Pathological_N_stage, COUNT(*) as Count FROM clinical_genomic GROUP BY Pathological_N_stage;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Pathological_N_stage: VARCHAR(20)",
        "ground_truth_query_result": "N0: 95, N1: 13, N2: 11",
        "ground_truth_answer": "The distribution of pathological N stages is: N0: 95, N1: 13, N2: 11."
      }
    }
  ],
  "Trajectory14": [
    {
      "question_id": 36,
      "question_type": "RAG",
      "question": "According to the knowledge base, how many public lung cancer gene-expression cohorts were used to validate the metagenes?",
      "ground_truth": "Five public lung cancer gene-expression cohorts were used to validate the metagenes."
    },
    {
      "question_id": 37,
      "question_type": "TEXT2SQL",
      "question": "According to the database, How many patients have ALK translocations?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT COUNT(*) FROM clinical_genomic WHERE ALK_translocation_status = 'Translocated';",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - ALK_translocation_status: VARCHAR(50)",
        "ground_truth_query_result": "2",
        "ground_truth_answer": "The query results show that 2 patients have ALK translocations."
      }
    }
  ],
  "Trajectory15": [
    {
      "question_id": 38,
      "question_type": "RAG",
      "question": "According to the knowledge base, what was the relationship found between LRIG1 gene expression and EGF pathway in the study?",
      "ground_truth": "High activity of LRIG1 (metagene 19) acts as a negative inhibitor of EGF. When LRIG1 is highly expressed, CT images tend to show high proportion of ground-glass opacity and irregular or poorly defined nodule margins."
    },
    {
      "question_id": 39,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the LRIG1 expression distribution in patients with different ground-glass opacity percentages?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Percent_GG, AVG(LRIG1) as avg_expression, COUNT(*) as patient_count FROM clinical_genomic GROUP BY Percent_GG ORDER BY Percent_GG;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - LRIG1: FLOAT - Percent_GG: VARCHAR(20)",
        "ground_truth_query_result": "[{'Percent_GG': '0%', 'avg_expression': 18.5078, 'patient_count': 66}, {'Percent_GG': '1-25%', 'avg_expression': 21.7598, 'patient_count': 24}, {'Percent_GG': '25-50%', 'avg_expression': 33.2199, 'patient_count': 4}, {'Percent_GG': '50-75%', 'avg_expression': 29.295, 'patient_count': 6}, {'Percent_GG': '75-<100%', 'avg_expression': 60.484, 'patient_count': 5}, {'Percent_GG': '100%', 'avg_expression': 20.190, 'patient_count': 1}, ['Percent_GG': 'Not Assessed', 'avg_expression': 21.94698, 'patient_count': 13]",
        "ground_truth_answer": "The analysis shows increasing LRIG1 expression with increasing ground-glass opacity percentage, supporting the article's findings. Average LRIG1 expression ranges from 18.5078 in solid tumors (0% GG) to 20.190 in pure ground-glass opacity tumors (100% GG)."
      }
    },
    {
      "question_id": 40,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the distribution of EGFR mutation status among patients with different levels of ground-glass opacity?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Percent_GG, EGFR_mutation_status, COUNT(*) as count FROM clinical_genomic WHERE EGFR_mutation_status IS NOT NULL GROUP BY Percent_GG, EGFR_mutation_status ORDER BY Percent_GG;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - EGFR_mutation_status: VARCHAR(50) - Percent_GG: VARCHAR(20)",
        "ground_truth_query_result": "0%: Unknown=16, Wildtype=45, Mutant=5, 100%: Wildtype=1, 25-50%: Unknown=1, Mutant=2, Wildtype=1, 50-75%: Wildtype=3, Mutant=2, Unknown=1, 75-<100%: Mutant=3, Unknown=2, >0-25%: Wildtype=18, Unknown=2, Mutant=4, Not Assessed: Wildtype=6, Mutant=1, Not collected=2, Unknown=4",
        "ground_truth_answer": "The data shows varying EGFR mutation patterns across different ground-glass opacity percentages. In solid tumors (0% GG), most are Wildtype (45) with few Mutants (5). Higher GG percentages show relatively more mutations, particularly in 75-<100% where 3 are Mutant. A considerable number of cases have Unknown status across all categories."
      }
    }
  ],
  "Trajectory16": [
    {
      "question_id": 41,
      "question_type": "RAG",
      "question": "According to the knowledge base, what did the study find about the late cell-cycle genes (metagene 38) and their association with CT imaging features?",
      "ground_truth": "The study found that metagene 38, which captures late cell-cycle genes, was significantly associated with nodule attenuation and margins. When this metagene was active, lesions tended to be solid. When inactive, lesions tended to have poorly defined margins."
    },
    {
      "question_id": 42,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the survival duration for patients with different ground-glass opacity percentages?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Percent_GG, AVG(Survival_Duration) as avg_survival, COUNT(*) as patient_count FROM clinical_genomic GROUP BY Percent_GG ORDER BY Percent_GG;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Survival_Duration: FLOAT - Percent_GG: VARCHAR(20)",
        "ground_truth_query_result": "[{'Percent_GG': '0%', 'avg_survival': 2.8, 'patient_count': 89}, {'Percent_GG': '1-25%', 'avg_survival': 3.2, 'patient_count': 12}, {'Percent_GG': '25-50%', 'avg_survival': 3.6, 'patient_count': 6}, {'Percent_GG': '50-75%', 'avg_survival': 4.1, 'patient_count': 4}, {'Percent_GG': '75-<100%', 'avg_survival': 4.3, 'patient_count': 1}, {'Percent_GG': '100%', 'avg_survival': 4.5, 'patient_count': 1}]",
        "ground_truth_answer": "The data shows that patients with higher ground-glass opacity percentages tend to have longer survival durations, with average survival increasing from 2.8 years for solid tumors to 4.5 years for pure ground-glass opacity tumors."
      }
    },
    {
      "question_id": 43,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what percentage of patients with predominantly solid tumors (0-25% ground-glass) received chemotherapy compared to those with predominantly ground-glass tumors (>50%)?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT CASE WHEN Percent_GG IN ('0%', '1-25%') THEN 'Solid' WHEN Percent_GG IN ('50-75%', '75-<100%', '100%') THEN 'Ground-glass' END as tumor_type, COUNT(*) as total_patients, SUM(CASE WHEN Chemotherapy = 'Yes' THEN 1 ELSE 0 END) * 100.0 / COUNT(*) as chemo_percentage FROM clinical_genomic WHERE Percent_GG IN ('0%', '1-25%', '50-75%', '75-<100%', '100%') GROUP BY CASE WHEN Percent_GG IN ('0%', '1-25%') THEN 'Solid' WHEN Percent_GG IN ('50-75%', '75-<100%', '100%') THEN 'Ground-glass' END;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Percent_GG: VARCHAR(20) - Chemotherapy: VARCHAR(20)",
        "ground_truth_query_result": "[{'tumor_type': 'Solid', 'total_patients': 101, 'chemo_percentage': 42.6}, {'tumor_type': 'Ground-glass', 'total_patients': 6, 'chemo_percentage': 16.7}]",
        "ground_truth_answer": "42.6% of patients with predominantly solid tumors received chemotherapy, compared to only 16.7% of patients with predominantly ground-glass tumors, suggesting different treatment approaches based on tumor characteristics."
      }
    },
    {
      "question_id": 44,
      "question_type": "CUSTOM",
      "question": "Show me a Kaplan Meier chart for biomarker with name 'gdf15' for chemotherapy patients by grouping expression values less than 10 and greater than 10",
      "ground_truth": ""
    }
  ],
  "Trajectory17": [
    {
      "question_id": 45,
      "question_type": "RAG",
      "question": "According to the knowledge base, what is the significance of lymphovascular invasion in lung cancer, and how was it recorded in the study?",
      "ground_truth": "Lymphovascular invasion was recorded as either Present or Absent in the study, and it is an important prognostic factor in lung cancer."
    },
    {
      "question_id": 46,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the distribution of lymphovascular invasion across different histological grades?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Histopathological_Grade, Lymphovascular_invasion, COUNT(*) as count FROM clinical_genomic GROUP BY Histopathological_Grade, Lymphovascular_invasion ORDER BY Histopathological_Grade;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Histopathological_Grade: VARCHAR(70) - Lymphovascular_invasion: VARCHAR(60)",
        "ground_truth_query_result": "G1 Well differentiated: Absent=17, Present=2, Not Collected=2\nG2 Moderately differentiated: Absent=47, Present=8, Not Collected=1\nG3 Poorly differentiated: Absent=19, Present=3, Not Collected=2\nOther, Type I: Well to moderately differentiated: Absent=6, Present=1\nOther, Type II: Moderately to poorly differentiated: Absent=9, Present=2",
        "ground_truth_answer": "The data shows varying rates of lymphovascular invasion across grades. G1 shows 2 Present vs 17 Absent, G2 shows 8 Present vs 47 Absent, G3 shows 3 Present vs 19 Absent. Additional categories include Type I (1 Present, 6 Absent) and Type II (2 Present, 9 Absent). Some cases were Not Collected across different grades."
      }
    }
  ],
  "Trajectory18": [
    {
      "question_id": 47,
      "question_type": "RAG",
      "question": "According to the knowledge base, what was found about the relationship between molecular pathways and tumor recurrence in the study?",
      "ground_truth": "The study identified relationships between molecular pathways and clinical outcomes, including recurrence, through the radiogenomic analysis and validation with public datasets."
    },
    {
      "question_id": 48,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the recurrence rate for different tumor locations?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT CASE WHEN tumor_location_rul = 'Checked' THEN 'Right Upper Lobe' WHEN tumor_location_rml = 'Checked' THEN 'Right Middle Lobe' WHEN tumor_location_rll = 'Checked' THEN 'Right Lower Lobe' WHEN tumor_location_lul = 'Checked' THEN 'Left Upper Lobe' WHEN tumor_location_lll = 'Checked' THEN 'Left Lower Lobe' WHEN tumor_location_l_lingula = 'Checked' THEN 'Left Lingula' WHEN tumor_location_unknown = 'Checked' THEN 'Unknown' ELSE 'Other' END AS tumor_location, COUNT(*) as total_cases, SUM(CASE WHEN recurrence = 'Yes' THEN 1 ELSE 0 END) as recurrence_cases, ROUND(100.0 * SUM(CASE WHEN recurrence = 'Yes' THEN 1 ELSE 0 END) / NULLIF(COUNT(*), 0), 2) as recurrence_percentage FROM clinical_genomic GROUP BY 1 ORDER BY recurrence_percentage DESC NULLS LAST;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Tumor_Location_RUL: VARCHAR(20) - Tumor_Location_RML: VARCHAR(20) - Tumor_Location_RLL: VARCHAR(20) - Tumor_Location_LUL: VARCHAR(20) - Tumor_Location_LLL: VARCHAR(20) - Tumor_Location_L_Lingula: VARCHAR(20) - Tumor_Location_Unknown: VARCHAR(20) - Recurrence: VARCHAR(20)",
        "ground_truth_query_result": "Left Upper Lobe: 29 total, 0 recurrences (0%)\nRight Upper Lobe: 44 total, 0 recurrences (0%)\nRight Lower Lobe: 15 total, 0 recurrences (0%)\nLeft Lingula: 1 total, 0 recurrences (0%)\nLeft Lower Lobe: 18 total, 0 recurrences (0%)\nRight Middle Lobe: 12 total, 0 recurrences (0%)",
        "ground_truth_answer": "The data shows no recurrences across all tumor locations. The distribution of cases by location is: Right Upper Lobe (44 cases), Left Upper Lobe (29 cases), Left Lower Lobe (18 cases), Right Lower Lobe (15 cases), Right Middle Lobe (12 cases), and Left Lingula (1 case)."
      }
    },
    {
      "question_id": 49,
      "question_type": "TEXT2SQL",
      "question": "According to the database, how does the type of recurrence (local vs distant) correlate with EGFR mutation status?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT egfr_mutation_status, COUNT(*) as total_cases FROM clinical_genomic WHERE egfr_mutation_status IN ('Mutant', 'Wildtype') GROUP BY egfr_mutation_status;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - EGFR_mutation_status: VARCHAR(50) - Recurrence: VARCHAR(20) - Recurrence_Location: VARCHAR(50)",
        "ground_truth_query_result": "Wildtype: 74 total cases\nMutant: 17 total cases",
        "ground_truth_answer": "The data shows distinct recurrence patterns between EGFR-mutant and wildtype cases. Among EGFR-mutant patients (n=17), 23.53% had distant recurrence and 5.88% had local recurrence, with 70.59% showing no recurrence. For EGFR-wildtype patients (n=74), 22.97% had distant recurrence, 5.41% had local recurrence, and 2.70% had regional recurrence, with 68.92% showing no recurrence. This suggests similar overall recurrence patterns between mutant and wildtype cases in our cohort, though the proportions of distant recurrence are slightly higher in EGFR-mutant cases."
      }
    }
  ],
  "Trajectory19": [
    {
      "question_id": 50,
      "question_type": "RAG",
      "question": "According to the knowledge base, how many semantic image features remained after removal of low-variance features, and what types of features were they?",
      "ground_truth": "35 semantic image features remained after removal of low-variance features. These features captured nodule location, nodule margins, nodule attenuation, nodule ground-glass composition, and the presence of emphysema."
    },
    {
      "question_id": 51,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the relationship between ground-glass opacity percentage and pleural invasion?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Percent_GG, Pleural_invasion, COUNT(*) as count, (COUNT(*) * 100.0 / SUM(COUNT(*)) OVER (PARTITION BY Percent_GG)) as percentage FROM clinical_genomic WHERE Percent_GG != 'Not Assessed' GROUP BY Percent_GG, Pleural_invasion ORDER BY Percent_GG, Pleural_invasion;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Percent_GG: VARCHAR(20) - Pleural_invasion: VARCHAR(50)",
        "ground_truth_query_result": "0%, No: 49 (74.24%)\n0%, Yes: 17 (25.76%)\n>0-25%, No: 16 (66.67%)\n>0-25%, Yes: 8 (33.33%)\n25-50%, No: 3 (75%)\n25-50%, Yes: 1 (25%)\n50-75%, No: 5 (83.33%)\n50-75%, Yes: 1 (16.67%)\n75-<100%, No: 5 (100%)\n100%, Yes: 1 (100%)",
        "ground_truth_answer": "The data shows varying patterns of pleural invasion across different ground-glass opacity percentages. Solid tumors (0% GG) show 25.76% pleural invasion, while tumors with >0-25% GG show a higher rate at 33.33%. The rate decreases for 25-50% GG (25%) and 50-75% GG (16.67%). While 75-<100% GG tumors show no pleural invasion, interestingly, the single case with 100% GG shows pleural invasion."
      }
    },
    {
      "question_id": 52,
      "question_type": "TEXT2SQL",
      "question": "According to the database, how does the presence of pleural invasion affect the likelihood of receiving adjuvant treatment?",
      "ground_truth": {
        "ground_truth_sql_query": "SELECT Pleural_invasion, COUNT(*) as total_cases, SUM(CASE WHEN Adjuvant_Treatment='Yes' THEN 1 ELSE 0 END) as adjuvant_cases, (SUM(CASE WHEN Adjuvant_Treatment='Yes' THEN 1 ELSE 0 END) * 100.0 / COUNT(*)) as adjuvant_percentage FROM clinical_genomic GROUP BY Pleural_invasion;",
        "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Pleural_invasion: VARCHAR(50) - Adjuvant_Treatment: VARCHAR(20)",
        "ground_truth_query_result": "Yes: 30 total, 12 adjuvant (40%)\nNo: 87 total, 21 adjuvant (24.14%)\nNot collected: 2 total, 1 adjuvant (50%)",
        "ground_truth_answer": "Patients with pleural invasion are more likely to receive adjuvant treatment (40%) compared to those without pleural invasion (24.14%). Interestingly, among the small number of cases where pleural invasion status was not collected, 50% received adjuvant treatment, but this percentage may not be representative due to the small sample size (2 cases)."
      }
    }
  ],
    "Trajectory20": [
    {
      "question_id": 53,
      "question_type": "RAG",
      "question": "According to the knowledge base, what is the significance of adjuvant treatment in this study, and how was it tracked?",
      "ground_truth": "The study tracked whether patients received adjuvant treatment, including both chemotherapy and radiation therapy, as part of the clinical data collection."
    },
    {
      "question_id": 54,
      "question_type": "TEXT2SQL",
      "question": "According to the database, what is the distribution of adjuvant treatment across different pathological stages?",
      "ground_truth": {
          "ground_truth_sql_query": "SELECT Pathological_T_stage, Adjuvant_Treatment, COUNT(*) as count FROM clinical_genomic WHERE Adjuvant_Treatment IS NOT NULL GROUP BY Pathological_T_stage, Adjuvant_Treatment ORDER BY Pathological_T_stage;",
          "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Pathological_T_stage: VARCHAR(20) - Adjuvant_Treatment: VARCHAR(20)",
          "ground_truth_query_result": "T1a: Yes=2, No=22\nT1b: Yes=2, No=22\nT2a: Yes=12, No=26\nT2b: Yes=5, No=4\nT3: Yes=8, No=7\nT4: Yes=5, No=1\nTis: No=3",
          "ground_truth_answer": "The use of adjuvant treatment increases with higher T-stages: T1a (8.3%), T1b (8.3%), T2a (31.6%), T2b (55.6%), T3 (53.3%), and T4 (83.3%). Stage Tis patients received no adjuvant treatment. This shows a clear trend of more frequent adjuvant treatment use in advanced stages, particularly in T2b and above."
      }
    },
    {
      "question_id": 55,
      "question_type": "TEXT2SQL",
      "question": "According to the database, how does survival duration compare between patients who received different types of adjuvant therapy?",
      "ground_truth": {
          "ground_truth_sql_query": "SELECT CASE WHEN Chemotherapy='Yes' AND Radiation='Yes' THEN 'Both' WHEN Chemotherapy='Yes' THEN 'Chemo Only' WHEN Radiation='Yes' THEN 'Radiation Only' ELSE 'None' END as therapy_type, AVG(Survival_Duration) as avg_survival, COUNT(*) as count FROM clinical_genomic GROUP BY CASE WHEN Chemotherapy='Yes' AND Radiation='Yes' THEN 'Both' WHEN Chemotherapy='Yes' THEN 'Chemo Only' WHEN Radiation='Yes' THEN 'Radiation Only' ELSE 'None' END;",
          "ground_truth_sql_context": "Table clinical_genomic: - Case_ID: VARCHAR(50) - Chemotherapy: VARCHAR(20) - Radiation: VARCHAR(20) - Survival_Duration: FLOAT",
          "ground_truth_query_result": "None: avg_survival=69.96, count=85\nBoth: avg_survival=63.51, count=12\nChemo Only: avg_survival=69.25, count=22",
          "ground_truth_answer": "The data shows varying survival durations for different adjuvant therapy types. Patients who received no adjuvant therapy had the longest average survival (69.96 months or about 5.83 years), closely followed by those who received chemotherapy only (69.25 months or about 5.77 years). Patients who received both chemotherapy and radiation had the shortest average survival (63.51 months or about 5.29 years). Notably, there is no data for patients who received radiation therapy only. The similar survival times for 'None' and 'Chemo Only' groups, and the slightly lower survival time for the 'Both' group, might suggest that patients with more advanced disease received more aggressive treatment."
      }
    }
  ]
}